1-(Azetidin-3-yl)butan-2-one

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 1-(Azetidin-3-yl)butan-2-one
• 英文别名: 1-(azetidin-3-yl)butan-2-one
• 化学式: C₇H₁₃NO
• 分子量: 127.18
• InChiKey: FVRZDMOZHDCHNF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0
• 重原子数：
  9
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.86
• 拓扑面积：
  29.1
• 氢给体数：
  1
• 氢受体数：
  2

文献信息

• [EN] SPIRO 1,3,4-THIADIAZOLINE DERIVATIVES AS KSP INHIBITORS<br/>[FR] DÉRIVÉS DE SPIRO 1,3,4-THIADIAZOLINE INHIBITEURS DE KSP
  申请人：SCHERING CORP

  公开号：WO2010132520A1

  公开（公告）日：2010-11-18

  The present invention relates to compounds of Formula (I), below, (wherein X, R1, R2, R3, p, ring A, and ring B are as defined herein). The present invention also relates to compositions (including pharmaceutically acceptable compositions) comprising these compounds, alone and in combination with one or more additional therapeutic agents, and to methods for their use in inhibiting KSP kinesin activity, and for treating cellular proliferative diseases or disorders associated with KSP kinesin activity.

  本发明涉及下式（I）的化合物（其中X、R1、R2、R3、p、环A和环B的定义如本文所述）。本发明还涉及包括这些化合物的组合物（包括药用组合物），单独或与一个或多个额外治疗剂结合使用的方法，以及用于抑制KSP肌动蛋白活性和治疗与KSP肌动蛋白活性相关的细胞增殖性疾病或疾病的方法。
• FUMAGILLOL HETEROCYCLIC COMPOUNDS AND METHODS OF MAKING AND USING SAME
  申请人：Zafgen, Inc.

  公开号：US20170066749A1

  公开（公告）日：2017-03-09

  Disclosed herein, in part, are fumagillol compounds and methods of use in treating medical disorders, such as obesity. Pharmaceutical compositions and methods of making fumagillol compounds are provided. The compounds are contemplated to have activity against methionyl aminopeptidase 2.
• US9682965B2
  申请人：——

  公开号：US9682965B2

  公开（公告）日：2017-06-20